Brachytherapy · 2025
Rectal spacers in high-dose-rate-brachytherapy: Optimizing peripheral zone radiation delivery.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cronkite Christopher A, Lakomy David, Baghwala Arjit, Pino Ramiro, Farach Andrew M
Аннотация
BACKGROUND: The utilization of rectal spacers (RS) in prostate cancer treated with definitive radiotherapy has been shown to provide rectal dose sparing, decreased rectal toxicity, and improved gastrointestinal quality-of-life metrics. This dose-sparing effect presents an opportunity for dose escalation to the prostate, potentially enhancing clinical and biochemical outcomes while minimizing adverse effects. Although the influence of RS on overall prostate dosimetry has yielded mixed findings, the specific impact on radiation delivery to the predominantly tumorigenic peripheral zone (PZ) remains largely unexamined. This study aims to evaluate the effects of RS on PZ dosimetry in prostate brachytherapy.
METHODS: A single-institution, retrospective analysis was conducted on patients who received two-fraction high-dose-rate brachytherapy (HDR-BT) for localized prostate cancer. Dosimetric parameters and biochemical outcomes were compared between consecutive patients who received intraoperative RS (RS+) and those who did not (RS-). Additional subset analysis was performed stratifying by prostate size. Comparisons were performed using the Mann-Whitney U test. Dosimetric parameters were assessed for the prostate, planning target volume, PZ, and organs at risk (OAR).
RESULTS: Between January 2020 and July 2024, a total of 92 patients who underwent HDR-BT were identified, of whom 46 (50%) were RS+. The contoured volumes of the prostate and PZ were comparable between the RS- and RS+ cohorts, with a median of 38.5 vs. 34.96 cm3 (p = 0.4475) and 11.25 vs. 10.25 (p = 0.1964), respectively, for the prostate and PZ. However, median PZ D90 was significantly higher in RS+ patients compared to RS- (RZ+ 115.65% vs. 110.25%, p < 0.0001). The increase in PZ D90 in the RS+ group was more pronounced in patients with smaller prostates (<40 cm3: RS+ 115.97% vs. 108.87%, p < 0.0001). Regarding organs at risk, the RS+ group exhibited a reduction in rectal Dmax (p < 0.0001), V20 (p = 0.0002), D80 (p < 0.0001), and D2cc (p < 0.0001); a decrease in urethral Dmax (p = 0.0017) and V110 (p = 0.0002); and an increase in bladder V75 and D80 (p < 0.0001).
CONCLUSIONS: As expected, RS HDR-BT successfully reduced rectal radiation exposure in this cohort. RS use is associated with increased radiation delivery to the PZ, potentially augmenting ablative dosing to the primary site of disease and the most likely zone for potential microscopic intraprostatic spread, as well as decreased urethral doses. This enhanced dose distribution within the PZ, with simultaneous improved urethral sparing, supports the incorporation of RS in HDR-BT. Whether this dosimetric enhancement results in long-term biochemical control or improved overall oncologic outcomes remains an ongoing area of investigation.
METHODS: A single-institution, retrospective analysis was conducted on patients who received two-fraction high-dose-rate brachytherapy (HDR-BT) for localized prostate cancer. Dosimetric parameters and biochemical outcomes were compared between consecutive patients who received intraoperative RS (RS+) and those who did not (RS-). Additional subset analysis was performed stratifying by prostate size. Comparisons were performed using the Mann-Whitney U test. Dosimetric parameters were assessed for the prostate, planning target volume, PZ, and organs at risk (OAR).
RESULTS: Between January 2020 and July 2024, a total of 92 patients who underwent HDR-BT were identified, of whom 46 (50%) were RS+. The contoured volumes of the prostate and PZ were comparable between the RS- and RS+ cohorts, with a median of 38.5 vs. 34.96 cm3 (p = 0.4475) and 11.25 vs. 10.25 (p = 0.1964), respectively, for the prostate and PZ. However, median PZ D90 was significantly higher in RS+ patients compared to RS- (RZ+ 115.65% vs. 110.25%, p < 0.0001). The increase in PZ D90 in the RS+ group was more pronounced in patients with smaller prostates (<40 cm3: RS+ 115.97% vs. 108.87%, p < 0.0001). Regarding organs at risk, the RS+ group exhibited a reduction in rectal Dmax (p < 0.0001), V20 (p = 0.0002), D80 (p < 0.0001), and D2cc (p < 0.0001); a decrease in urethral Dmax (p = 0.0017) and V110 (p = 0.0002); and an increase in bladder V75 and D80 (p < 0.0001).
CONCLUSIONS: As expected, RS HDR-BT successfully reduced rectal radiation exposure in this cohort. RS use is associated with increased radiation delivery to the PZ, potentially augmenting ablative dosing to the primary site of disease and the most likely zone for potential microscopic intraprostatic spread, as well as decreased urethral doses. This enhanced dose distribution within the PZ, with simultaneous improved urethral sparing, supports the incorporation of RS in HDR-BT. Whether this dosimetric enhancement results in long-term biochemical control or improved overall oncologic outcomes remains an ongoing area of investigation.